A Multicenter, Open Label, Nonrandomized, Non Interventional, Observational, Safety and Efficacy Study in Hospitalized Subjects Using Intravenous NovoRapid (Insulin Aspart)
Latest Information Update: 30 Oct 2016
Price :
$35 *
At a glance
- Drugs Insulin aspart (Primary)
- Indications Hyperglycaemia
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 30 May 2012 New trial record